Bel­licum out­lines a few quick steps the FDA wants be­fore lift­ing its hold on lead cell ther­a­py, shares rise

Bel­licum rocked in­vestors at the end of last month with news that its “safer” lead cell ther­a­py had been put on hold by the FDA. And this morn­ing the biotech is fol­low­ing up with an ex­pla­na­tion of what it needs to do to get that hold lift­ed.

By Bel­licum’s ac­count, that’s not a lot.

In a state­ment out this morn­ing Bel­licum $BLCM says that it needs to re­vise its study pro­to­cols, with reg­u­la­tors look­ing for “more com­pre­hen­sive mon­i­tor­ing and man­age­ment of neu­ro­tox­i­c­i­ty.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER